mRNA-1273

## 16.2.3 Participants Excluded From the Efficacy Analysis

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Clinical Study Report mRNA-1273-P201 Addendum 1

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Page 1 of 348 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		_	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason		
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2011030	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2011042	Yes	Yes	Yes	Day 29	No/ There was no immunogenicity result at corresponding visit Yes	No/ There was no immunogenicity result at corresponding visit Yes		No/There was no immunogenicity result at corresponding visit	

<sup>[1]</sup> Based on samples from the First Lot.

Page 2 of 348 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011042	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011043	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011056	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 3 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	- Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011056	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011057	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011060	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 4 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2011060	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2011064	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2011067	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 5 of 348 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

	Solicited Safety Set/ Exclusion Reason				Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	:/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011067	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011068	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011069	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 6 of 348 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		-	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2011069	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2011070	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/ There was no immunogenicity result at corresponding visit		Yes Yes No/There was no immunogenicity result at tcorresponding visit	
US2011086	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 7 of 348 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

	Solicited Safety Set/ Exclusion Reason				Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	:/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011086	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011088	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021061	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 8 of 348 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021061	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021062	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021073	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 9 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason	_	Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021073	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Post-baseline COVID-19 infection prior to the visit	3 4
US2021078	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021082	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 10 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

	Safety Set	Solicited Safety Set/ Exclusion Reason		_	Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021082	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Post-baseline COVID-19 infection prior to the visit, COVID-19 related prohibited med prio to the visit	result at corresponding
US2021089	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021094	Yes	Yes	No/Did not receive Vaccinati on #2	Day 29	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	Vaccination #2;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation
				Day 57	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	Vaccination #2;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 12 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		_	is Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason		
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2021094	Yes	Yes	No/Did not receive Vaccinati on #2	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; Serum collection ou of window; Other study deviation; Post-baseline COVID-19 infection	<pre>immunogenicity result at corresponding</pre>	
US2021096	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 13 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021096	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021107	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021111	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 14 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021111	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021135	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021137	Yes	Yes	Yes	Day 29	Yes	Yes		No/Post-baseline COVID-19 infection prior to the visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 15 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set	c/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	- Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021137	Yes	Yes	Yes	Day 57	Yes	Yes  No/ There was no immunogenicity result at corresponding visit	out of window; Othe study deviation; Post-baseline COVID-19 infection prior to the visit	2 2
US2021138	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 16 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021138	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021144	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes No/Other study deviation Yes	Yes No/Other study deviation No/There was no immunogenicity result at corresponding visit
US2021155	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 17 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021155	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Post-baseline COVID-19 infection prior to the visit	2 4
US2021161	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Solicited Safety Set/ Exclusion Reason					_	s Set/Exclusion ason	Per-Protocol Set	c/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021162	Yes	Yes	No/Did not receive Vaccinati on #2	Day 29	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at corresponding visit; Other study deviation No/Did not receive Vaccination #2;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Other study deviation No/Did not receive Vaccination #2; tSerum collection out of window; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 19 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		4	is Set/Exclusion eason	Per-Protocol Set	col Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2021162	Yes	Yes	No/Did not receive Vaccinati on #2	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; Serum collection ou of window; Other	No/Did not receive Vaccination #2; tThere was no immunogenicity result at corresponding visit; Other study deviation	
US2021175	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/Post-baseline COVID-19 infection prior to the visit	_	
US2031001	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 20 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031001	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031009	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031014	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 21 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031014	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031022	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031023	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 22 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031023	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031029	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031038	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 23 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031038	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031040	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031041	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031041	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031043	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Solicited Safety Set/ Exclusion Reason					_	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason		
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2031045	Yes	Yes	No/Did not receive Vaccinati on #2	Day 29	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at corresponding visit;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set	
				Day 57	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at corresponding visit;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set	

<sup>[1]</sup> Based on samples from the First Lot.

Page 26 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		_	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031045	Yes	Yes	No/Did not receive Vaccinati on #2	Day 209	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at corresponding visit;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set
US2031048	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031049	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 27 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031049	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031058	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031071	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 28 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason	_	_	is Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason		
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2031071	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2031074	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2031081	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes		Yes No/Post-baseline COVID-19 infection prior to the visit	

<sup>[1]</sup> Based on samples from the First Lot.

Page 29 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		-	is Set/Exclusion Reason	Per-Protocol Set	c/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031081	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Post-baseline COVID-19 infection prior to the visit	
US2041005	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041011	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	-,	Yes nNo/Serum collection rout of window; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 30 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason	Full Analysis Set/Exclusion Reason			Per-Protocol Set/Exclusion Reason		
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2041011	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2041014	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2041019	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes		Yes on No/Serum collection erout of window; Other study deviation	

<sup>[1]</sup> Based on samples from the First Lot.

Page 31 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		_	sis Set/Exclusion Reason	Per-Protocol Se	et/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041019	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041020	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041022	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 32 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		_	s Set/Exclusion	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041022	Yes	Yes	Yes	Day 209	Yes	no	No/Post-baseline COVID-19 infection prior to the visit	
US2041025	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041029	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 33 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	:/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041029	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041034	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041042	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 34 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041042	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041043	Yes	Yes	No/Did not receive Vaccinati on #2	Day 29	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at corresponding visit;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set

<sup>[1]</sup> Based on samples from the First Lot.

Page 35 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		_	S Set/Exclusion	Per-Protocol Set	c/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	- Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041043	Yes	Yes	No/Did not receive Vaccinati on #2	Day 57	No/ There was	No/ There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set
				Day 209	no	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at corresponding visit;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set
US2041056	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

	Solicited Safety Set/ Exclusion Reason				-	Set/Exclusion ason	Per-Protocol Set/Exclusion Reason		
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2041056	Yes	Yes	Yes	Day 209	no	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit	
US2041059	Yes	Yes	No/Did not receive Vaccinati on #2	Day 29	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	<pre>immunogenicity result at corresponding visit;</pre>	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set; Other study deviation	

<sup>[1]</sup> Based on samples from the First Lot.

Page 37 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		4	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason		
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2041059	Yes	Yes	No/Did not receive Vaccinati on #2	Day 57	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at corresponding visit;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set; Other study deviation	
				Day 209	no	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at corresponding visit;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set; Other study deviation	
US2041062	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 38 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041062	Yes	Yes	Yes	Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
US2041078	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041086	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 39 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safet	icited ty Set/ on Reason		-	s Set/Exclusion ason	Per-Protocol Set	Per-Protocol Set/Exclusion Reason		
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]		
US2041086	Yes	Yes	Yes	Day 209	no	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at tcorresponding visit		
US2041089	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit		
US2041090	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes		

<sup>[1]</sup> Based on samples from the First Lot.

Page 40 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041090	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051022	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes		Yes on No/Serum collection erout of window; Other study deviation
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051035	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 41 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	- Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051035	Yes	Yes	Yes	Day 57	Yes	Yes  No/ There was no immunogenicity result at corresponding visit		_
US2051036	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2051044	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 42 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051044	Yes	Yes	Yes	Day 57	Yes	Yes	,	Neutralizing Antibody [1]  on No/Serum collection erout of window; Other study deviation No/There was no immunogenicity result at corresponding visit  Yes Yes No/There was no immunogenicity result at
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity
US2061003	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes No/There was no immunogenicity
US2061015	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 43 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason Safety Set/			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2061015	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2061018	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/Post-baseline COVID-19 infection prior to the visit	2 2
US2061021	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 44 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	- Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2061021	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2061022	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2061025	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	No/Dosing error No/Dosing error	No/Dosing error No/Dosing error

<sup>[1]</sup> Based on samples from the First Lot.

Page 45 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2061025	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Dosing error	No/Dosing error; There was no immunogenicity result at corresponding visit
US2061032	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071012	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 46 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason	_	_	is Set/Exclusion Reason	Per-Protocol Set	c/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071012	Yes	Yes	Yes	Day 209	Yes	no	No/Post-baseline COVID-19 infection prior to the visit	3 1
US2071014	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071017	Yes	Yes	Yes	Day 29	Yes	Yes	No/Other study deviation	No/Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 47 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071017	Yes	Yes	Yes	Day 57	Yes	Yes  No/ There was no immunogenicity result at corresponding visit	out of window; Oth study deviation No/Other study deviation	on No/Serum collection erout of window; Other study deviation No/There was no immunogenicity result at corresponding visit; Other study deviation
US2071022	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071042	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 48 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071042	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071044	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071046	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 49 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2071046	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2071049	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2071050	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 50 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2071050	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Post-baseline COVID-19 infection prior to the visit		
US2071059	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2071062	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 51 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason	_	_	ls Set/Exclusion eason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071062	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Post-baseline COVID-19 infection prior to the visit	
US2071064	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071066	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 52 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			_	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071066	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071070	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/Post-baseline COVID-19 infection prior to the visit	
US2071072	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 53 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		_	s Set/Exclusion	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071072	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Post-baseline COVID-19 infection prior to the visit	
US2081026	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081033	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 54 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2081033	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2081038	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2081042	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 55 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason	_	_	is Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081042	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081046	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/Post-baseline COVID-19 infection prior to the visit	
US2081049	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 56 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

	Solicited Safety Set/ Exclusion Reason			_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081049	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081057	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081058	Yes	Yes	No/Did not receive Vaccinati on #2	Day 29	Yes	Yes	No/Did not receive Vaccination #2; Other study deviation	No/Did not receive Vaccination #2; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

	Solicited Safety Set/ Exclusion Reason				Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081058	3 Yes	Yes No/Did not receive Vaccinati on #2	- :	Vaccination #2; Serum collection ou of window; Other	No/Did not receive Vaccination #2; tSerum collection out of window; Other study deviation			
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; Serum collection ou of window; Other	No/Did not receive Vaccination #2; tThere was no immunogenicity result at corresponding visit; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 58 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

	Solicited Safety Set/ Exclusion Reason			_	_	s Set/Exclusion	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011020	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011029	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011048	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 59 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

	Solicited Safety Set/ Exclusion Reason				Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011048	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011051	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 60 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Safe	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011055	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/Non study COVID-19 vaccine prior to the visit	Yes Yes No/There was no immunogenicity result at corresponding visit; Non study COVID-19 vaccine prior to the visit
US2011061	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011084	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 61 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	- Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011084	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011087	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011090	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 62 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011090	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011091	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011092	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 63 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Solicited Safety Set/ Exclusion Reason			_	is Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011092	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011093	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 64 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011093	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011095	Yes	Yes	Yes	Day 29	No/ There was no immunogenicity result at corresponding visit	no immunogenicity result at	immunogenicity result at	No/There was no immunogenicity result at tcorresponding visit
				Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 65 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Safe	icited ty Set/ on Reason	_	Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011102	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021058	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021064	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 66 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	- Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021064	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021084	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021090	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 67 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	- Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021090	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021147	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021166	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 68 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Solicited Safety Set/ Exclusion Reason			Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021166	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021167	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021179	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 69 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Safe	icited ty Set/ on Reason		Full Analy	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2021179	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2031002	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2031004	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 70 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Safe	icited ty Set/ on Reason		-	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2031004	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2031011	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/ There was no immunogenicity result at corresponding visit		Yes Yes No/There was no immunogenicity result at tcorresponding visit	
US2031016	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 71 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	- Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031016	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031030	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031042	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 72 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Safe	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031042	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031051	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031056	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 73 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031056	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031057	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031063	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 74 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031063	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031066	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031072	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 75 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031072	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031080	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041002	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 76 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Solicited Safety Set/ Exclusion Reason			_	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041002	Yes	Yes	Yes	Day 209	no	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at tcorresponding visit
US2041003	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041006	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 77 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Safe	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041006	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041007	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041012	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 78 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Safe	icited ty Set/ on Reason	_	_	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041012	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041013	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041016	Yes	Yes	Yes	Day 29	Yes	Yes	collection out of	mout of window; Serum

<sup>[1]</sup> Based on samples from the First Lot.

Page 79 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			_	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First	Second Injection	- Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041016	Yes	Yes	Yes	Day 57	Yes  No/ There was no immunogenicity result at corresponding visit	Yes  No/ There was no immunogenicity result at corresponding visit	study deviation No/Vaccination #2 out of window; Ther	No/Vaccination #2 rout of window; Other study deviation No/Vaccination #2 eout of window; There was no immunogenicity result at corresponding visit; Other study deviation
US2041023	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 80 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Safe	icited ty Set/ on Reason	_	_	s Set/Exclusion eason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041027	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041030	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041036	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 81 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Solicited Safety Set/ Exclusion Reason			-	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041036	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041047	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/ There was no immunogenicity result at corresponding visit	prior to the visit No/There was no immunogenicity result at corresponding visit; Post-baseline COVID-19 infection	Yes No/Post-baseline COVID-19 infection prior to the visit No/There was no immunogenicity result at corresponding visit; Post-baseline COVID-19 infection prior to the visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 82 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

	Solicited Safety Set/ Exclusion Reason					all Analysis Set/Exclusion Reason Per-Protocol Set/Exclusion		
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041049	Yes	Yes	Yes	Day 29	Yes	Yes	collection out of	mout of window; Serum
				Day 57	Yes	Yes	No/Vaccination #2 out of window; Othe study deviation	No/Vaccination #2 rout of window; Other study deviation
				Day 209	no immunogenicity result at	No/ There was no immunogenicity result at corresponding visit	No/Vaccination #2 out of window; Ther	2
US2041051	. Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 83 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041051	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041053	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 84 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Safe	icited ty Set/ on Reason		-	s Set/Exclusion ason	Per-Protocol Set	L/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041055	Yes	Yes	No/Did not receive Vaccinati on #2	Day 29	result at	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at corresponding visit;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set; Other study deviation
				Day 57	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at corresponding visit;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 85 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason	Full Analysis Set/Exclusion Reason			Per-Protocol Set/Exclusion Reason		
	Safety Set		on noabon	=				Tel Hotocol Bee, Bactablei Reason	
Subject ID	Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2041055	Yes	Yes	No/Did not receive Vaccinati on #2	Day 209	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	<pre>immunogenicity result at corresponding visit;</pre>	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set; Other study deviation	
US2041058	Yes	Yes	No/Did not receive Vaccinati on #2	Day 29	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at corresponding visit;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set; Other study deviation	

<sup>[1]</sup> Based on samples from the First Lot.

Page 86 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

	Solicited Safety Set/ Exclusion Reason					s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason		
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2041058	Yes	Yes	No/Did not receive Vaccinati on #2	Day 57	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at corresponding visit;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set; Other study deviation	
				Day 209	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at corresponding visit;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set; Other study deviation	

<sup>[1]</sup> Based on samples from the First Lot.

Page 87 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

	Solicited Safety Set/ Exclusion Reason					s Set/Exclusion ason	Per-Protocol Se	t/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041064	Yes	Yes	Yes	Day 29	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	collection out of window; Other stud deviation No/Vaccination #2 out of window; Ther	mout of window; Serum collection out of ywindow; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 88 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Solicited Safety Set/ Exclusion Reason			_	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041064	Yes	Yes	Yes	Day 209	no immunogenicity result at	No/ There was no immunogenicity result at corresponding visit	· · · · · · · · · · · · · · · · · · ·	No/Vaccination #2 recout of window; There was no immunogenicity result at corresponding visit; Other study deviation
US2041071	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041075	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 89 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041075	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041076	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041077	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 90 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041077	Yes	Yes	Yes	Day 209	no	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at tcorresponding visit
US2041088	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/ There was no immunogenicity result at corresponding visit		Yes Yes No/There was no immunogenicity result at tcorresponding visit
US2041091	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 91 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041091	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041092	Yes	Yes	Yes	Day 29	Yes	Yes	collection out of window; Other stud deviation No/Vaccination #2	mout of window; Serum collection out of ywindow; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 92 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Safe <sup>.</sup> Exclusi	olicited fety Set/ sion Reason		Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041092	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Vaccination #2 out of window; Othe study deviation	No/Vaccination #2 erout of window; There was no immunogenicity result at corresponding visit; Other study deviation
US2051008	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2051009	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 93 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason	_	_	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051009	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051010	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2051011	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes		Yes on No/Serum collection erout of window; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 94 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason	_	_	is Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051011	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Serum collection out of window	n No/There was no immunogenicity result at corresponding visit
US2051018	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 95 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Solicited Safety Set/ Exclusion Reason		_	_	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051027	Yes	Yes		Day 29 Day 57	Yes Yes	Yes Yes		Yes on No/Serum collection erout of window; Other study deviation
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051031	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2051032	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 96 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Safe Exclusi	icited ty Set/ on Reason	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051032	Yes	Yes	Yes	Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
US2051033	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	out of window; Othe study deviation	Yes nNo/Serum collection rout of window; Other study deviation
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051034	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 97 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Safe	icited ty Set/ on Reason	Full Analysis Set/Exclusion Reason			Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051034	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051038	Yes	Yes	No/Did not receive Vaccinati on #2	Day 29	Yes	Yes	No/Did not receive Vaccination #2	No/Did not receive Vaccination #2
				Day 57	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at	No/Did not receive Vaccination #2; There was no immunogenicity result at tcorresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 98 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

	Solicited Safety Set/ Exclusion Reason				-	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051038	Yes	Yes	No/Did not receive Vaccinati on #2	Day 209	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at	No/Did not receive Vaccination #2; There was no immunogenicity result at tcorresponding visit
US2051040	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2051042	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 99 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051042	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051043	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 100 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051043	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051048	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/Serum collection out of window	Yes Yes nNo/There was no immunogenicity result at corresponding visit
US2051050	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 101 of 348 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051050	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2061001	Yes	Yes	Yes	Day 29	Yes	Yes	collection out of window; Other stud deviation No/Vaccination #2	mout of window; Serum collection out of ywindow; Other study deviation No/Vaccination #2
							out of window; Othe study deviation	rout of window; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 102 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Safe <sup>.</sup> Exclusi	icited ty Set/ on Reason	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2061001	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Vaccination #2 out of window; Othe study deviation	No/Vaccination #2 rout of window; There was no immunogenicity result at corresponding visit; Other study deviation
US2061006	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2061009	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 103 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	:/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2061009	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2061011	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2061013	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 104 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		_	is Set/Exclusion Reason	Per-Protocol Se	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2061013	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2061019	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2061026	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 105 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2061026	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071001	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071003	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 106 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071003	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071004	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071029	Yes	Yes	Yes	Day 29	Yes	Yes	No/Other study deviation	No/Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 107 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

	Solicited Safety Set/ Exclusion Reason					s Set/Exclusion ason	Per-Protocol Set/Exclusion Reaso		
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2071029	Yes	Yes	Yes	Day 57	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit; Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation	
				Day 209	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit; Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation	
US2071030	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	.,	Yes onNo/Serum collection erout of window; Other study deviation	

<sup>[1]</sup> Based on samples from the First Lot.

Page 108 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

	Solicited Safety Set/ Exclusion Reason				_	s Set/Exclusion	Per-Protocol Set/Exclusion Reason		
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2071030	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit	
US2071032	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2071033	Yes	Yes	Yes	Day 29	Yes	Yes	No/Other study deviation No/Other study deviation	No/Other study deviation No/Other study deviation	

<sup>[1]</sup> Based on samples from the First Lot.

Page 109 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

	Solicited Safety Set/ Exclusion Reason				Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071033	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation
US2071063	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071067	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	-,	Yes on No/Serum collection erout of window; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 110 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Safe	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071067	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071074	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071081	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 111 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071081	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081036	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/Post-baseline COVID-19 infection prior to the visit	
US2081039	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 112 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason	_		s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081039	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081041	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/ There was no immunogenicity result at corresponding visit		Yes Yes No/There was no immunogenicity result at tcorresponding visit
US2081052	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 113 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		Safe	icited ty Set/ on Reason		_	.s Set/Exclusion eason Per-Protocol Set/Exclusion Reasor			
Subject ID	Safety Set Exclusion Criteria	First	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2081052	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2081054	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2081059	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 114 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		Safet	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason		
Subject ID	Safety Set Exclusion Criteria	First	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2081059	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit	

<sup>[1]</sup> Based on samples from the First Lot.

Page 115 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

	Solicited Safety Set/ Exclusion Reason				_	s Set/Exclusion	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011018	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011019	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011039	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 116 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	./ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2011039	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2011041	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/ There was no immunogenicity result at corresponding visit	corresponding	Yes Yes No/There was no immunogenicity result at corresponding visit; Other study deviation	
US2011046	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 117 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011046	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011050	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011059	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 118 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011059	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011065	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011080	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 119 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe	icited ty Set/ on Reason		_	is Set/Exclusion Reason	Per-Protocol Se	et/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011080	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit
US2011085	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 120 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011085	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011089	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011103	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 121 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe <sup>.</sup> Exclusi	icited ty Set/ on Reason	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011103	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021059	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 122 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

	Solicited Safety Set/ Exclusion Reason			_	_	s Set/Exclusion eason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021063	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021067	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021068	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 123 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Se	t/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021068	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Serum collectio out of window	nNo/There was no immunogenicity result at corresponding visit
US2021074	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021080	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 124 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021080	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021093	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021099	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 125 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021099	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021101	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021121	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 126 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

Solicited Safety Set/ Exclusion Reaso					_	is Set/Exclusion Reason	Per-Protocol Se	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2021121	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2021145	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2021151	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 127 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021151	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021154	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021164	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 128 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

	Solicited Safety Set/ Exclusion Reason				Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021164	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021180	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021182	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes No/Serum collection out of window	Yes nNo/Serum collection out of window

<sup>[1]</sup> Based on samples from the First Lot.

Page 129 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason		_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021182	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031012	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 130 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason	_	Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031013	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031019	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031020	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 131 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031020	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031021	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031026	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 132 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031026	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031027	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031033	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 133 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031033	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031035	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031037	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 134 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031037	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031047	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031050	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 135 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	:/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031050	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031060	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031062	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 136 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

	Solicited Safety Set/ Exclusion Reason				_	ris Set/Exclusion Reason Per-Protocol Set/Exclusion Rea		
Subject ID	Safety Set Exclusion Criteria	First	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031062	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031073	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031079	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 137 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			_	is Set/Exclusion eason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031079	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031084	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041008	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes		Yes on No/Serum collection erout of window; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 138 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041008	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041010	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041024	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 139 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041024	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041026	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041041	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 140 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041041	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041046	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041048	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 141 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason		_	Full Analysis Set/Exclusion Reason		Per-Protocol Set	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2041048	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2041060	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes		Yes nNo/Serum collection rout of window; Other study deviation	
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2041061	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 142 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe <sup>.</sup> Exclusi	icited ty Set/ on Reason	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041061	Yes	Yes	Yes	Day 57	Yes	Yes  No/ There was no immunogenicity result at corresponding	out of window; Other study deviation Yes	on No/Serum collection erout of window; Other study deviation No/There was no immunogenicity result at corresponding visit
US2041073	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	visit  Yes Yes No/ There was no immunogenicity result at corresponding	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041079	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	visit Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 143 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041079	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041080	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041084	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 144 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041084	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051001	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2051002	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 145 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051002	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051003	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/ There was no immunogenicity result at corresponding visit		Yes Yes No/There was no immunogenicity result at corresponding visit
US2051012	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 146 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2051012	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit	
US2051013	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 147 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			_	is Set/Exclusion eason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051013	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051017	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes		Yes nNo/Serum collection erout of window; Other study deviation
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051019	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 148 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051019	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051020	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 149 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051024	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 57	Yes	Yes	-,	n No/Serum collection erout of window; Other study deviation
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051025	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes		Yes nNo/Serum collection erout of window; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 150 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051025	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051026	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2051028	Yes	Yes	No/Did not receive Vaccinati on #2	Day 29	Yes	Yes	No/Did not receive Vaccination #2; Other study deviation	No/Did not receive Vaccination #2; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 151 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason	_	_	s Set/Exclusion	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051028	Yes	Yes	No/Did not receive Vaccinati on #2	Day 57	Yes	result at	No/Did not receive Vaccination #2; Serum collection ou of window; Other study deviation	Vaccination #2;
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; Serum collection ou of window; Other study deviation	Vaccination #2;
US2051029	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 152 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

	Solicited Safety Set/ Exclusion Reason			_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051029	Yes	Yes		Day 57	Yes	Yes	No/Serum collectionNo/Serum collection out of window; Otherout of window; Otherout of window; Otherout deviation study deviation	
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051030	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2051045	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 153 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

-	Solicited Safety Set/ Exclusion Reason				_	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051045	Yes	Yes	Yes	Day 209	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit
US2061008	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/Serum collection out of window	Yes Yes NO/There was no immunogenicity result at corresponding visit
US2061010	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 154 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2061010	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2061020	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2061023	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 155 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			-	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2061023	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit	
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2061024	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	No/Dosing error No/Dosing error	No/Dosing error No/Dosing error	

<sup>[1]</sup> Based on samples from the First Lot.

Page 156 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2061024	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/Dosing error; There was no immunogenicity result at corresponding visit
US2061027	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071002	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 157 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason		_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071002	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071016	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071026	Yes	Yes	Yes	Day 29	No/ There was no immunogenicity result at baseline	Yes	No/Not in Full Analysis Set; Othe study deviation	No/Other study rdeviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 158 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe	icited ty Set/ on Reason	Full Analysis Set/Exclusion Reason			Per-Protocol Set	Per-Protocol Set/Exclusion Reason	
Subject	Safety Set Exclusion	/ First	Second	_	Binding	Neutralizing		Neutralizing	
ID	Criteria	Injection	Injection	Visit	Antibody	Antibody [1]	Binding Antibody	Antibody [1]	
US2071026	yes	Yes	Yes	Day 57	No/ There was no immunogenicity result at baseline	Yes	No/Not in Full Analysis Set; Other study deviation	No/Other study rdeviation	
				Day 209	no	no	No/Not in Full Analysis Set; Other study deviation	No/There was no rimmunogenicity result at corresponding visit; Other study deviation	
US2071036	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visi	

<sup>[1]</sup> Based on samples from the First Lot.

Page 159 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

	Solicited Safety Set/ Exclusion Reason				Full Analy	rsis Set/Exclusion Reason	Per-Protocol Se	t/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071038	Yes	Yes	Yes	Day 29	Yes	Yes	out of window; Seru collection out of	No/Vaccination #2 mout of window; Serum collection out of ywindow; Other study deviation
				Day 57	Yes	Yes		No/Vaccination #2 erout of window; Other study deviation
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	-, "	No/Vaccination #2 erout of window; There was no immunogenicity result at corresponding visit; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 160 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			_	s Set/Exclusion ason		
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071039	Yes	Yes	Yes	Day 29	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	·	No/Vaccination #2 eout of window; There was no immunogenicity result at corresponding visit; Other study deviation
				Day 57	Yes	Yes	No/Vaccination #2 out of window; Othe study deviation	No/Vaccination #2 rout of window; Other study deviation
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Vaccination #2	4

<sup>[1]</sup> Based on samples from the First Lot.

Page 161 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

	Solicited Safety Set/ Exclusion Reason			_	_	s Set/Exclusion eason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071040	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071051	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071068	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 162 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	- Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071068	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071069	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071071	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 163 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe	icited ty Set/ on Reason		Full Analy	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2071071	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2071073	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2071077	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 164 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071077	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081023	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081025	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 165 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

	Solicited Safety Set/ Exclusion Reason				Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	:/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081025	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081028	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081045	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 166 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Se	et/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081045	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081051	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081062	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 167 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081062	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081063	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081064	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 168 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081064	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 169 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

	Solicited Safety Set/ Exclusion Reason			_	_	s Set/Exclusion eason	Per-Protocol Se	t/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011007	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011011	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011023	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 170 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011023	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011109	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011114	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 171 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011114	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011116	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011120	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 172 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011120	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011124	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011126	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 173 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analy	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2011126	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2011130	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2011131	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 174 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		_	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011131	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011142	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011145	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 175 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Se	et/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011145	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011152	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at baseline and corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set

<sup>[1]</sup> Based on samples from the First Lot.

Page 176 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analy	sis Set/Exclusion Reason	Per-Protocol Se	et/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011152	Yes	Yes	Yes	Day 57	Yes Yes	No/ There was no immunogenicity result at baseline and corresponding visit No/ There was no immunogenicity result at baseline and corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2011155	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 177 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011155	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011156	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at baseline and corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set

<sup>[1]</sup> Based on samples from the First Lot.

Page 178 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011156	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at baseline and corresponding visit No/ There was no immunogenicity result at baseline and corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2011157	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 179 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011157	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021015	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021021	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 180 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analy	sis Set/Exclusion Reason			
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2021021	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2021022	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2021043	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 181 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	sis Set/Exclusion Reason			
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2021043	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2021130	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2021185	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 182 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason		
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2021185	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2021189	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2021196	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 183 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

	Solicited Safety Set/ Exclusion Reason			_		Per-Protocol Set/Exclusion Reason		
Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
es.	Yes	Yes	Day 209	no immunogenicity result at	result at		No/There was no immunogenicity result at tcorresponding visit	
es.	Yes	Yes	Day 29	Yes	Yes	collection out of window; Other stud deviation No/Vaccination #2	mout of window; Serum collection out of ywindow; Other study deviation No/Vaccination #2	
	xclusion riteria es	Safet Exclusi afety Set/ xclusion First riteria Injection es Yes	Safety Set/ Exclusion Reason  afety Set/ xclusion First Second riteria Injection Injection  es Yes Yes	Safety Set/ Exclusion Reason  afety Set/ xclusion First Second riteria Injection Injection Visit  es Yes Yes Day 209  es Yes Yes Day 29	Safety Set/ Exclusion Reason  afety Set/ xclusion First Second Binding riteria Injection Injection Visit Antibody  es Yes Yes Day 209 No/ There was no immunogenicity result at corresponding visit  es Yes Yes Day 29 Yes	Safety Set/ Exclusion Reason  afety Set/ xclusion First Second Reason  es Yes Yes Day 209 No/ There was no no immunogenicity result at corresponding visit  es Yes Yes Day 29 Yes Yes  Safety Set/Exclusion Reason  Reason  Reason  Reason  No/ There was no no immunogenicity immunogenicity result at corresponding visit  es Yes Yes Day 29 Yes Yes	Safety Set/ Exclusion Reason  afety Set/ xclusion First Second riteria Injection Injection Visit Antibody Antibody [1]  es Yes Yes Day 209 No/ There was No/ There was no immunogenicity result at corresponding visit  es Yes Yes Day 29 Yes Yes No/Vaccination #2 out of window; Other studied deviation  Full Analysis Set/Exclusion Reason Per-Protocol Set Reason No/There was no Per-Protocol Set Reason No/There was no Per-Protocol Set Reason	

<sup>[1]</sup> Based on samples from the First Lot.

Page 184 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			_	s Set/Exclusion ason	Per-Protocol Se	t/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	:/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021198	Yes	Yes	Yes	Day 209	no	No/ There was no immunogenicity result at corresponding visit	out of window; Ther was no immunogenicity	No/Vaccination #2 reout of window; There was no immunogenicity result at corresponding visit; Other study deviation
US2021206	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 185 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		-	s Set/Exclusion	Per-Protocol Set	:/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	First	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021207	Yes	Yes	Yes	Day 29	Yes	Yes	collection out of	mout of window; Serum
				Day 57	Yes	Yes	No/Vaccination #2 out of window; Othe study deviation	No/Vaccination #2 rout of window; Other study deviation
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Vaccination #2 out of window; Othe study deviation	No/Vaccination #2 rout of window; There was no immunogenicity result at corresponding visit; Other study deviation
US2021219	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 186 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason	_	_	sis Set/Exclusion Reason	et/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021219	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021222	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit.	Yes	No/There was no immunogenicity result at corresponding visit
				Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 187 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			_	s Set/Exclusion	Per-Protocol Se	et/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031085	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031089	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031092	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 188 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Se	et/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031092	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031095	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031098	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 189 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason	_	_	nalysis Set/Exclusion Reason Per-Protocol Set/Exclusion Rea			
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2031098	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2031100	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2031102	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes		Yes No/Post-baseline COVID-19 infection prior to the visit	

<sup>[1]</sup> Based on samples from the First Lot.

Page 190 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		_	s Set/Exclusion	Per-Protocol Set	Per-Protocol Set/Exclusion Reason		
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]		
US2031102	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Post-baseline COVID-19 infection prior to the visit			
US2031103	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit		
US2031110	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes		

<sup>[1]</sup> Based on samples from the First Lot.

Page 191 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason		
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2031110	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2031116	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2031124	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 192 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031124	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031125	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031129	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031129	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031131	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

	Solicited Safety Set/ Exclusion Reason				Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041102	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at baseline and corresponding visit No/ There was no immunogenicity result at baseline and corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set

<sup>[1]</sup> Based on samples from the First Lot.

Page 195 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		_	is Set/Exclusion Reason Per-Protocol Set/Exclusion Re		
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041102	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at baseline and corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2041114	Yes	Yes	Yes	Day 29	Yes	Yes Yes	collection out of window; Other stud deviation No/Vaccination #2	mout of window; Serum collection out of ywindow; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 196 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

	Solicited Safety Set/ Exclusion Reason				_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2041114	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Vaccination #2 out of window; Othe study deviation	No/Vaccination #2 rout of window; There was no immunogenicity result at corresponding visit; Other study deviation	
US2041115	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/ There was no immunogenicity result at corresponding visit		Yes Yes No/There was no immunogenicity result at tcorresponding visit	
US2041121	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 197 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041121	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041132	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041142	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 198 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		-	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041142	Yes	Yes	Yes	Day 209	no	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at tcorresponding visit
US2041146	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041151	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 199 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041151	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041152	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041166	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 200 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analy	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2041166	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2051055	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2051063	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051063	Yes	Yes	Yes	Day 209	no	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at tcorresponding visit
US2051072	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	out of window; Othe study deviation; Post-baseline COVID-19 infection	Yes nNo/Serum collection rout of window; Other study deviation; Post-baseline COVID-19 infection prior to the visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 202 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

	Solicited Safety Set/ Exclusion Reason				_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2051072	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Post-baseline COVID-19 infection prior to the visit		
US2051073	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2051086	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 203 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		_	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051086	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051087	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2051089	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 204 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051089	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051098	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2051112	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 205 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051112	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2061035	Yes	Yes	Yes	Day 29	Yes	Yes	collection out of window; Other stud deviation No/Vaccination #2	mout of window; Serum collection out of ywindow; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason	_	_	sis Set/Exclusion Reason	Per-Protocol Set	tocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2061035	Yes	Yes	Yes	Day 209	Yes	result at	No/Vaccination #2 out of window; Othe study deviation; Post-baseline COVID-19 infection prior to the visit		
US2061043	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	

<sup>[1]</sup> Based on samples from the First Lot.

Page 207 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		_	s Set/Exclusion	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	- Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2061046	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/Post-baseline COVID-19 infection prior to the visit	
US2061051	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/Serum collection out of window	Yes Yes No/There was no immunogenicity result at corresponding visit
US2061055	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 208 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			_	s Set/Exclusion	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2061055	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071005	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/Post-baseline COVID-19 infection prior to the visit	
US2071041	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 209 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited Ty Set/ on Reason		_	s Set/Exclusion	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071041	Yes	Yes	Yes	Day 209	Yes	no	No/Post-baseline COVID-19 infection prior to the visit	
US2071084	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071085	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 210 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2071085	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2071086	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2071088	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 211 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

	Solicited Safety Set/ Exclusion Reason				_	s Set/Exclusion	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071088	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071092	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/Post-baseline COVID-19 infection prior to the visit	2 2
US2071094	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 212 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe Exclusi	icited ty Set/ on Reason	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071094	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071098	Yes	Yes	Yes	Day 29	Yes	Yes	No/Other study deviation	No/Other study deviation
				Day 57	Yes	Yes	No/Other study deviation	No/Other study deviation
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation
US2071100	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes
				Day 57	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071100	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071102	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Se	et/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071103	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at baseline and corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
				Day 57	Yes	No/ There was no immunogenicity result at baseline and corresponding visit	No/Serum collection out of window	onNo/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set

<sup>[1]</sup> Based on samples from the First Lot.

Page 215 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071103	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at baseline and corresponding visit		No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2071105	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at baseline and corresponding visit		No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set

<sup>[1]</sup> Based on samples from the First Lot.

Page 216 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071105	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at baseline and corresponding visit No/ There was no immunogenicity result at baseline and corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2081004	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 217 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081004	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081005	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 218 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081007	Yes	No/Did not contribut e any solicited AR data for Vaccinati on #1	Yes	Day 29	Yes	Yes	Yes	Yes
				Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
US2081015	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 219 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081015	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081017	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081029	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 220 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		Full Analy	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2081029	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2081030	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2081065	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 221 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081065	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081066	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081073	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Solicited Safety Set/ Exclusion Reason			-	Full Analysis Set/Exclusion Reason		t/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081073	Yes	Yes	Yes	Day 209	no	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at tcorresponding visit
US2081077	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081080	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 223 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe <sup>-</sup>	icited ty Set/ on Reason		_	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081080	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081087	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081097	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 224 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		_	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081097	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081103	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081104	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

	Solicited Safety Set/ Exclusion Reason				_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2081104	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2081113	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/ There was no immunogenicity result at corresponding visit		Yes Yes No/There was no immunogenicity result at tcorresponding visit	
US2081119	Yes	Yes	Yes	Day 29	Yes	Yes	collection out of	mout of window; Serum	

<sup>[1]</sup> Based on samples from the First Lot.

Page 226 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		Safe	icited ty Set/ on Reason		_	s Set/Exclusion	Per-Protocol Set/Exclusion Reason	
	Safety Set			<del>-</del>			-	
Subject ID	Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081119	Yes	Yes	Yes	Day 57	Yes	Yes	No/Vaccination #2 out of window; Othe study deviation	No/Vaccination #2 rout of window; Other study deviation
				Day 209	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	·	No/Vaccination #2 eout of window; There was no immunogenicity result at corresponding visit; Other study deviation
US2081125	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/ There was no immunogenicity result at corresponding visit		Yes Yes No/There was no immunogenicity result at tcorresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 227 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe <sup>.</sup> Exclusi	icited ty Set/ on Reason	_	-	s Set/Exclusion eason	Per-Protocol Se	t/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	First	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011012	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011014	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011032	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 228 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	:/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011032	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011040	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011117	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 229 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe <sup>-</sup>	icited ty Set/ on Reason	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011117	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011123	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit.	Yes	No/There was no immunogenicity result at corresponding visit
				Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 230 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

		Safe	icited ty Set/ on Reason		_	is Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011125	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 57	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit
US2011127	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 231 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Solicited Safety Set/ _ Exclusion Reason			_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2011127	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2011137	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 232 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

	Solicited Safety Set/ Exclusion Reason			_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011137	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011138	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 233 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Solicited Safety Set/ Exclusion Reason			_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2011153	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	
				Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	
US2021004	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 234 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

	Solicited Safety Set/ Exclusion Reason				_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2021004	Yes	Yes	Yes	Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit	
US2021012	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2021018	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 235 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021018	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021019	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021020	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 236 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	:/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021020	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021045	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021047	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 237 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021047	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021133	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021190	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 238 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021190	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021192	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021205	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 239 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
	Safety Set		Ton neadon	_		reabon	Tel Hotelet Bee, Enclusion Reason	
Subject ID	Exclusion Criteria	First	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021205	o Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit
US2021216	5 Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit
				Day 57	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 240 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe	icited ty Set/ on Reason	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021216	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021217	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 241 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

Solicited Safety Set/ Exclusion Reason					_	sis Set/Exclusion Reason			
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2021220	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
				Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit	
US2021226	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 242 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 50 µg

		Safe	icited ty Set/ on Reason	_	_	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021226	Yes	Yes	Yes	Day 209	no	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit
US2031086	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit.	Yes	No/There was no immunogenicity result at corresponding visit
				Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 243 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 50 µg

	Solicited Safety Set/ Exclusion Reason			_	_	s Set/Exclusion	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031096	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031097	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031104	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 244 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Se	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2031104	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2031105	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2031106	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 245 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

Solicited Safety Set/ Exclusion Reason					_	sis Set/Exclusion Reason	Per-Protocol Set	:/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031106	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031107	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	out of window Yes	Yes nNo/Serum collection out of window No/There was no immunogenicity result at corresponding visit
US2031108	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 246 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe <sup>-</sup>	icited ty Set/ on Reason	Full Analysis Set/Exclusion Reason Per-P:			Per-Protocol Se	otocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2031108	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2031109	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2031114	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 247 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe <sup>-</sup>	icited ty Set/ on Reason	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031114	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031121	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 248 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 50 µg

		Safe	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031128	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041094	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041100	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 249 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041100	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit
US2041103	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at baseline and corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set

<sup>[1]</sup> Based on samples from the First Lot.

Page 250 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

		Safe	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Se	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2041103	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at baseline and corresponding visit No/ There was no immunogenicity result at baseline and corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	
US2041104	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 251 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

		Safe	icited ty Set/ on Reason	_	-	s Set/Exclusion ason Per-Protocol Set/Exclusion Reas		
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041104	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041106	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
				Day 209	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at		No/There was no immunogenicity result at tcorresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 252 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

	Safety Set	Safe <sup>.</sup> Exclusi	icited ty Set/ on Reason	_	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2041109	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2041111	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2041113	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 253 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041113	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041118	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041119	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 254 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe <sup>-</sup>	icited ty Set/ on Reason	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041119	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041127	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit.	Yes	No/There was no immunogenicity result at corresponding visit
				Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 255 of 348 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041130	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041139	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit
				Day 57	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 256 of 348 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

	Solicited Safety Set/ Exclusion Reason				_	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041139	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041145	Yes	Yes	Yes	Day 29 Day 57 Day 209	no	Yes Yes No/ There was no immunogenicity result at corresponding visit		Yes Yes No/There was no immunogenicity result at corresponding visit
US2041150	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 257 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

	Solicited Safety Set/ Exclusion Reason			_	Full Analy	vsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041150	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041155	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 258 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Solicited Safety Set/ Exclusion Reason		_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051057	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2051059	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	out of window; Other study deviation Yes	Yes nNo/Serum collection erout of window; Other study deviation No/There was no immunogenicity result at corresponding visit
US2051060	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 259 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

	Solicited Safety Set/ Exclusion Reason				Full Analy	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2051060	Yes	Yes	Yes	Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit	
US2051066	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2051068	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Se	et/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051068	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051071	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 261 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051078	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
				Day 57	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set

<sup>[1]</sup> Based on samples from the First Lot.

Page 262 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Solicited Safety Set/ Exclusion Reason			_	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051081	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
				Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2051092	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 263 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 50 µg

	Solicited Safety Set/ Exclusion Reason				Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051092	Yes	Yes	Yes	Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
US2051093	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2051094	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 264 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051094	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051095	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 265 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

	Solicited Safety Set/ Exclusion Reason			_	_	s Set/Exclusion	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051096	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2051099	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2051100	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 266 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

	Solicited Safety Set/ Exclusion Reason			_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051100	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051103	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 267 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051105	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
				Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2051107	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051107	Yes	Yes	Yes	Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
US2051109	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 269 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051109	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2061037	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Serum collection out of window	nNo/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe	icited ty Set/ on Reason		_	sis Set/Exclusion Reason	Per-Protocol Se	et/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	:/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2061053	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit No/ There was no immunogenicity result at corresponding visit	Yes	Yes No/There was no immunogenicity result at corresponding visit  No/There was no immunogenicity result at corresponding visit
US2061057	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 271 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

	Solicited Safety Set/ Exclusion Reason				Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	:/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2061057	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2061064	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2061068	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 272 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2061068	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071007	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071024	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 273 of 348 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe	icited ty Set/ on Reason		_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2071024	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2071025	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2071083	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 274 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

		Safe	icited ty Set/ on Reason	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071083	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit
US2071090	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 275 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe <sup>-</sup>	icited ty Set/ on Reason	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071090	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071099	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit.	Yes	No/There was no immunogenicity result at corresponding visit
				Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe	icited ty Set/ on Reason		-	s Set/Exclusion ason	Per-Protocol Se	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2071101	Yes	Yes	Yes	Day 29 Day 57 Day 209	result at corresponding visit No/ There was no	Yes  No/ There was no immunogenicity result at corresponding visit  No/ There was no immunogenicity result at corresponding visit	corresponding visit; Other study deviation No/There was no immunogenicity	No/Other study deviation No/There was no immunogenicity result at corresponding visit; Other study deviation No/There was no immunogenicity result at corresponding visit; Other study deviation	
US2071104	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071104	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071106	Yes	Yes	No/Did not receive Vaccinati on #2	Day 29	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	Vaccination #2;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

	Solicited Safety Set/ Exclusion Reason					ysis Set/Exclusion Reason	Per-Protocol Set	c/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071106	5 Yes	Yes	No/Did not receive Vaccinati on #2	Day 57	Yes	Yes  No/ There was no	No/Did not receive Vaccination #2; Serum collection ou of window; Other study deviation; Post-baseline COVID-19 infection prior to the visit No/Did not receive Vaccination #2; Serum collection ou of window; Other	No/Did not receive Vaccination #2; tSerum collection out of window; Other study deviation; Post-baseline COVID-19 infection prior to the visit No/Did not receive Vaccination #2; tThere was no immunogenicity result at corresponding visit;

<sup>[1]</sup> Based on samples from the First Lot.

Page 279 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe	icited ty Set/ .on Reason	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081003	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081009	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081020	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 280 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe <sup>-</sup>	icited ty Set/ on Reason	_	_	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081020	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081070	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 57 Day 209	Yes No/ There was no immunogenicity result at corresponding visit	Yes No/ There was no immunogenicity result at corresponding visit		Yes No/There was no immunogenicity result at tcorresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 281 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe <sup>-</sup>	icited ty Set/ on Reason	_	_	s Set/Exclusion eason	Per-Protocol Set	c/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081071	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit
US2081085	Yes	Yes	Yes	Day 29	Yes	Yes	collection out of	mout of window; Serum

<sup>[1]</sup> Based on samples from the First Lot.

Page 282 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

	Safety Set	Safe Exclusi	icited ty Set/ on Reason	_	-	is Set/Exclusion Reason	Per-Protocol Set	c/Exclusion Reason
Subject ID	Exclusion Criteria	First	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081085	Yes	Yes	Yes	Day 57	Yes	Yes	study deviation	rout of window; Other study deviation
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	collection out of window; Other stud	mout of window; There was no
US2081090	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 283 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 50 µg

	Solicited Safety Set/ Exclusion Reason			_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081090	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081092	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081100	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at baseline	Yes	No/Not in Full Analysis Set

<sup>[1]</sup> Based on samples from the First Lot.

Page 284 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe <sup>-</sup>	icited ty Set/ .on Reason		Full Analy	sis Set/Exclusion Reason	Per-Protocol Se	t/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081100	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at baseline		on No/Serum collection erout of window; Not in Full Analysis Set; Other study deviation
				Day 209	Yes	No/ There was no immunogenicity result at baseline and corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2081110	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 285 of 348 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081110	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081112	Yes	Yes	Yes	Day 29 Day 57	Yes	Yes Yes	collection out of	mout of window; Serum collection out of ywindow; Other study deviation
							out of window; Othe study deviation	<pre>rout of window; Other   study deviation</pre>

<sup>[1]</sup> Based on samples from the First Lot.

Page 286 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	./ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081112	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/Vaccination #2 erout of window; There was no immunogenicity result at corresponding visit; Other study deviation
US2081118	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 287 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		Safe	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason		
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2081123	Yes	Yes	No/Did not receive Vaccinati on #2	Day 29	Yes	Yes	Vaccination #2;	No/Did not receive Vaccination #2; tSerum collection out of window; Other study deviation	
				Day 57	Yes	Yes	Vaccination #2;	No/Did not receive Vaccination #2; tSerum collection out of window; Other study deviation	
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; Serum collection ou of window; Other	No/Did not receive Vaccination #2;	

<sup>[1]</sup> Based on samples from the First Lot.

Page 288 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

	Solicited Safety Set/ Exclusion Reason				_	s Set/Exclusion	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011004	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011009	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011028	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 289 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011028	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011113	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at baseline	Yes	No/Not in Full Analysis Set
				Day 57	Yes	No/ There was no immunogenicity result at baseline and corresponding visit		No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analy	ysis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011113	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at baseline and corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2011118	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 291 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

	Solicited Safety Set/ Exclusion Reason				_	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011118	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011121	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/ There was no immunogenicity result at corresponding visit		Yes Yes No/There was no immunogenicity result at tcorresponding visit
US2011122	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 292 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	:/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011122	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2011128	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011139	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

	Solicited Safety Set/ Exclusion Reason			_	-	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011139	Yes	Yes	Yes	Day 209	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at tcorresponding visit
US2011149	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 294 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		_	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2011159	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2011162	Yes	Yes	Yes	Day 29	result at baseline	No/ There was no immunogenicity result at baseline No/ There was	Analysis Set No/Not in Full	No/Not in Full Analysis Set  No/Not in Full
					no immunogenicity result at baseline	no immunogenicity result at baseline	Analysis Set	Analysis Set

<sup>[1]</sup> Based on samples from the First Lot.

Page 295 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

	Solicited Safety Set/ Exclusion Reason				_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2011162	Yes	Yes	Yes	Day 209	no	No/ There was no immunogenicity result at baseline and corresponding visit	No/Not in Full Analysis Set	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	
US2021003	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2021007	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 296 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	:/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021007	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021011	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/Serum collection out of window	Yes Yes nNo/There was no immunogenicity result at corresponding visit
US2021031	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 297 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	:/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021031	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021114	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021115	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 298 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021115	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021186	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021208	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes No/Serum collection out of window	Yes nNo/Serum collection out of window

<sup>[1]</sup> Based on samples from the First Lot.

Page 299 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 μg

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021208	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021211	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021214	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 300 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ .on Reason	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021214	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit
US2021215	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes No/Serum collectio out of window	Yes nNo/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 301 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	- Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021215	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021218	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021230	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 302 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason	_	Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021230	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Serum collection out of window; Post-baseline COVID-19 infection prior to the visit	<pre>immunogenicity result at corresponding</pre>
US2021232	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2021234	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason		_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2021234	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031091	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit.	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 304 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Safe	icited ty Set/ on Reason		_	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031093	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2031101	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/ There was no immunogenicity result at corresponding visit		Yes Yes No/There was no immunogenicity result at tcorresponding visit
US2031111	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 305 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		_	Full Analysis Set/Exclusion Reason		t/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031111	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031112	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding	out of window; Othe study deviation Yes	Yes nNo/Serum collection rout of window; Other study deviation No/There was no immunogenicity result at corresponding visit
US2031122	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	visit Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 306 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	:/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2031122	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041096	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041107	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 307 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

	Qa fahar Qah	Safe Exclusi	icited ty Set/ on Reason	_	Full Analy	ysis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041107	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041108	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit; Not in Full Analysis
				Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set

<sup>[1]</sup> Based on samples from the First Lot.

Page 308 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analy	ysis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041108	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis
US2041112	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041117	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 309 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Safe	icited ty Set/ on Reason		_	is Set/Exclusion Reason	Per-Protocol Se	ol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2041117	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2041120	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 310 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041120	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041122	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041123	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 311 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041123	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041125	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 312 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ .on Reason	_	Full Analy	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041126	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041131	Yes	Yes	Yes	Day 29	Yes	Yes	out of window; Seru collection out of	No/Vaccination #2 mout of window; Serum collection out of ywindow; Other study deviation
				Day 57	Yes	Yes	out of window; Seru collection out of	No/Vaccination #2 mout of window; Serum collection out of ywindow; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 313 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		_	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041131	Yes	Yes	Yes	Day 209	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	•	No/Vaccination #2 eout of window; There was no immunogenicity result at corresponding visit; Other study deviation
US2041136	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2041138	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 314 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

	Solicited Safety Set/ Exclusion Reason			_	Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041138	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit
US2041144	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 315 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason		_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2041144	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041149	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 316 of 348 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Safe	icited ty Set/ on Reason	_	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2051054	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2051064	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit	
US2051069	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 317 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051069	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051070	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2051074	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 318 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Safe	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051074	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit
US2051075	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 319 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051075	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051077	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2051084	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051084	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051085	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 321 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051088	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
				Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
				Day 209	no	No/ There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visi	No/There was no immunogenicity result at

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		_	s Set/Exclusion ason	Per-Protocol Set/Exclusion Reason		
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2051097	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
				Day 57 Day 209	Yes No/ There was no immunogenicity result at corresponding visit	Yes No/ There was no immunogenicity result at corresponding visit		Yes No/There was no immunogenicity result at tcorresponding visit	
US2051101	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes	

<sup>[1]</sup> Based on samples from the First Lot.

Page 323 of 348 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2051101	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2051102	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit	
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	

<sup>[1]</sup> Based on samples from the First Lot.

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051104	Yes	Yes	No/Did not receive Vaccinati on #2	Day 29	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at corresponding visit;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set
				Day 57	result at	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at corresponding visit;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set

<sup>[1]</sup> Based on samples from the First Lot.

Page 325 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051104	Yes	Yes	No/Did not receive Vaccinati on #2	Day 209	result at	No/ There was no immunogenicity result at corresponding visit	Vaccination #2; There was no immunogenicity result at corresponding visit;	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; sNot in Full Analysis Set
US2051106	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2051108	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 326 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			_	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2051108	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051111	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2061036	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 327 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set	c/Exclusion Reason
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2061036	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2061045	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes No/Serum collection out of window	Yes nNo/Serum collection out of window

<sup>[1]</sup> Based on samples from the First Lot.

Page 328 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2061045	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2061063	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071006	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 329 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071006	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071013	Yes	Yes	Yes	Day 29	Yes	Yes	collection out of	No/Vaccination #2 mout of window; Serum collection out of ywindow; Other study deviation
				Day 57	Yes	Yes	-, "	No/Vaccination #2 rout of window; Other study deviation

<sup>[1]</sup> Based on samples from the First Lot.

Page 330 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason	_	_	sis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071013	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	-, "	No/Vaccination #2 rout of window; There was no immunogenicity result at corresponding visit; Other study deviation
US2071037	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071043	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 331 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071043	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071082	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071087	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 332 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071087	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071089	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2071091	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 333 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071091	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit
US2071093	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 334 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071093	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071095	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 335 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason		_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2071096	Yes	Yes	Yes	Day 29	result at corresponding visit	visit	corresponding visit; Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation
				Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	No/Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation
US2081001	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 336 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081001	Yes	Yes	Yes	Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
US2081002	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081014	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 337 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081014	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081016	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081019	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 338 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>-</sup>	icited ty Set/ on Reason		Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081019	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081035	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081069	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 339 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

	Solicited Safety Set/ Exclusion Reason				_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]	
US2081069	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	
US2081072	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit.		No/There was no immunogenicity result at corresponding visit	
				Day 57 Day 209	Yes No/ There was no immunogenicity result at corresponding visit	Yes No/ There was no immunogenicity result at corresponding visit		Yes No/There was no immunogenicity result at tcorresponding visit	

<sup>[1]</sup> Based on samples from the First Lot.

Page 340 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081075	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 57 Day 209	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
US2081076	Yes	Yes	Yes	Day 29	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 341 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

	Solicited Safety Set/ Exclusion Reason			_	Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081076	Yes	Yes	Yes	Day 57	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081081	Yes	Yes	Yes	Day 29	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
				Day 57	Yes	Yes	Yes	Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 342 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 μg

		Safe	icited ty Set/ on Reason	_	Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081081	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081088	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 343 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Safe	icited ty Set/ on Reason		Full Analysis Set/Exclusion  Reason Per-Protocol Set/Exclusion			
Subject ID	Safety Set Exclusion Criteria	:/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081091	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit No/ There was no immunogenicity result at corresponding visit	Yes	Yes No/There was no immunogenicity result at corresponding visit  No/There was no immunogenicity result at corresponding visit
US2081093	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 344 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Safe <sup>.</sup> Exclusi	icited ty Set/ on Reason	_	Full Analy	rsis Set/Exclusion Reason	Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081093	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081099	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes	Yes No/There was no immunogenicity result at corresponding visit
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 345 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081108	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit
US2081116	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes Yes	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes Yes	Yes Yes No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 346 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		Solicited Safety Set/ Exclusion Reason			Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria		Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081117	Yes	Yes	Yes	Day 29	Yes	Yes	collection out of	mout of window; Serum
			Day 57	Yes	Yes	No/Vaccination #2 out of window; Othe study deviation	No/Vaccination #2 rout of window; Other study deviation	
				Day 209	Yes	No/ There was no immunogenicity result at corresponding visit	No/Vaccination #2	-
US2081120	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 347 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

-	Solicited Safety Set/ Exclusion Reason				Full Analysis Set/Exclusion Reason		Per-Protocol Set/Exclusion Reason	
Subject ID	Safety Set Exclusion Criteria	/ First Injection	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081120	Yes	Yes	Yes	Day 209	No/ There was no immunogenicity result at corresponding visit	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit
US2081121	Yes	Yes	Yes	Day 29 Day 57 Day 209	Yes Yes No/ There was no immunogenicity result at corresponding visit	Yes Yes No/ There was no immunogenicity result at corresponding visit		Yes Yes No/There was no immunogenicity result at corresponding visit
US2081129	Yes	Yes	Yes	Day 29 Day 57	Yes Yes	Yes Yes	Yes Yes	Yes Yes

<sup>[1]</sup> Based on samples from the First Lot.

Page 348 of 348
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.1 Analysis Sets 1 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason			Per-Protocol Set/Exclusion Reason		
Subject ID	Safety Set Exclusion Criteria	First	Second Injection	Visit	Binding Antibody	Neutralizing Antibody [1]	Binding Antibody	Neutralizing Antibody [1]
US2081129	Yes	Yes	Yes	Day 209	Yes	No/ There was no immunogenicity result at corresponding visit		No/There was no immunogenicity result at corresponding visit

<sup>[1]</sup> Based on samples from the First Lot.

Page 1 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		et for Neutralizi		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2011030	Yes	Yes	Yes	Yes	Yes	Yes
US2011042	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes
US2011043	Yes	Yes	Yes	Yes	Yes	Yes
US2011056	Yes	Yes	Yes	Yes	Yes	Yes
US2011057	Yes	Yes	Yes	Yes	Yes	Yes
US2011060	Yes	Yes	Yes	Yes	Yes	Yes
US2011064	Yes	Yes	Yes	Yes	Yes	Yes
US2011067	Yes	Yes	Yes	Yes	Yes	Yes
US2011068	Yes	Yes	Yes	Yes	Yes	Yes
US2011069	Yes	Yes	Yes	Yes	Yes	Yes
US2011070	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit

Page 2 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		sis Set for Neutra rom All Lots/Excl		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason			
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2011086	Yes	Yes	Yes	Yes	Yes	Yes	
US2011088	Yes	Yes	Yes	Yes	Yes	Yes	
US2021061	Yes	Yes	Yes	Yes	Yes	Yes	
US2021062	Yes	Yes	Yes	Yes	Yes	Yes	
US2021073	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit	
US2021078	Yes	Yes	Yes	Yes	Yes	Yes	
US2021082	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit; COVID-19 related prohibited med prior to the visit	
US2021089	Yes	Yes	Yes	Yes	Yes	Yes	

Page 3 of 66 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

-	_	et for Neutralizi	_	Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason			
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2021094	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	Yes	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Other study deviation	Serum collection out of window; Other study deviation;	
US2021096	Yes	Yes	Yes	Yes	Yes	Yes	
US2021107	Yes	Yes	Yes	Yes	Yes	Yes	
US2021111	Yes	Yes	Yes	Yes	Yes	Yes	
US2021135	Yes	Yes	Yes	Yes	Yes	Yes	

Page 4 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

	-	sis Set for Neutra rom All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason			
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2021137	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit	No/Serum collection out of window; Other study deviation; Post-baseline COVID-19 infection prior to the visit	No/Post-baselin e COVID-19 infection prior to the visit	
US2021138	Yes	Yes	Yes	Yes	Yes	Yes	
US2021144	Yes	Yes	Yes	Yes	No/Other study deviation	Yes	
US2021155	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit	
US2021161	Yes	Yes	Yes	Yes	Yes	Yes	

Page 5 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		et for Neutralizi		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason			
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2021162	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation	
US2021175	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit	
US2031001	Yes	Yes	Yes	Yes	Yes	Yes	
US2031009	Yes	Yes	Yes	Yes	Yes	Yes	
US2031014	Yes	Yes	Yes	Yes	Yes	Yes	
US2031022	Yes	Yes	Yes	Yes	Yes	Yes	
US2031023	Yes	Yes	Yes	Yes	Yes	Yes	
US2031029	Yes	Yes	Yes	Yes	Yes	Yes	
US2031038	Yes	Yes	Yes	Yes	Yes	Yes	

Page 6 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

	_	et for Neutralizi ll Lots/Exclusion	-	Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2031040	Yes	Yes	Yes	Yes	Yes	Yes
US2031041	Yes	Yes	Yes	Yes	Yes	Yes
US2031043	Yes	Yes	Yes	Yes	Yes	Yes
US2031045	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2031048	Yes	Yes	Yes	Yes	Yes	Yes
US2031049	Yes	Yes	Yes	Yes	Yes	Yes
US2031058	Yes	Yes	Yes	Yes	Yes	Yes
US2031071	Yes	Yes	Yes	Yes	Yes	Yes
US2031074	Yes	Yes	Yes	Yes	Yes	Yes

Page 7 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		sis Set for Neutra rom All Lots/Excl		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason			
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2031081	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit	No/Post-baselin e COVID-19 infection prior to the visit	
US2041005	Yes	Yes	Yes	Yes	Yes	Yes	
US2041011	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	
US2041014	Yes	Yes	Yes	Yes	Yes	Yes	
US2041019	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	
US2041020	Yes	Yes	Yes	Yes	Yes	Yes	
US2041022	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit	
US2041025	Yes	Yes	Yes	Yes	Yes	Yes	

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

	_	et for Neutralizi	=	Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2041029	Yes	Yes	Yes	Yes	Yes	Yes
US2041034	Yes	Yes	Yes	Yes	Yes	Yes
US2041042	Yes	Yes	Yes	Yes	Yes	Yes
US2041043	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2041056	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit

Page 9 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		et for Neutralizi		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2041059	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation
US2041062	Yes	Yes	Yes	Yes	Yes	Yes
US2041078	Yes	Yes	Yes	Yes	Yes	Yes
US2041086	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2041089	Yes	Yes	Yes	Yes	Yes	Yes
US2041090	Yes	Yes	Yes	Yes	Yes	Yes

Page 10 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		sis Set for Neutra rom All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason			
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2051022	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	
US2051035	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	No/Post-baselin e COVID-19 infection prior to the visit	
US2051036	Yes	Yes	Yes	Yes	Yes	Yes	
US2051044	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	
US2061003	Yes	Yes	Yes	Yes	Yes	Yes	
US2061015	Yes	Yes	Yes	Yes	Yes	Yes	
US2061018	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit	

Page 11 of 66 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		is Set for Neutra om All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason			
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2061021	Yes	Yes	Yes	Yes	Yes	Yes	
US2061022	Yes	Yes	Yes	Yes	Yes	Yes	
US2061025	Yes	Yes	Yes	No/Dosing error	No/Dosing error	No/Dosing error	
US2061032	Yes	Yes	Yes	Yes	Yes	Yes	
US2071012	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit	
US2071014	Yes	Yes	Yes	Yes	Yes	Yes	
US2071017	Yes	Yes	Yes	No/Other study deviation	No/Serum collection out of window; Other study deviation	No/Other study deviation	
US2071022	Yes	Yes	Yes	Yes	Yes	Yes	
US2071042	Yes	Yes	Yes	Yes	Yes	Yes	
US2071044	Yes	Yes	Yes	Yes	Yes	Yes	
US2071046	Yes	Yes	Yes	Yes	Yes	Yes	

Page 12 of 66 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		sis Set for Neutra rom All Lots/Exclu			ol Set for Neutral rom All Lots/Exclu	_
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2071049	Yes	Yes	Yes	Yes	Yes	Yes
US2071050	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit
US2071059	Yes	Yes	Yes	Yes	Yes	Yes
US2071062	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit
US2071064	Yes	Yes	Yes	Yes	Yes	Yes
US2071066	Yes	Yes	Yes	Yes	Yes	Yes
US2071070	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit
US2071072	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit
US2081026	Yes	Yes	Yes	Yes	Yes	Yes

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		sis Set for Neutra rom All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2081033	Yes	Yes	Yes	Yes	Yes	Yes
US2081038	Yes	Yes	Yes	Yes	Yes	Yes
US2081042	Yes	Yes	Yes	Yes	Yes	Yes
US2081046	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit
US2081049	Yes	Yes	Yes	Yes	Yes	Yes
US2081057	Yes	Yes	Yes	Yes	Yes	Yes
US2081058	Yes	Yes	Yes	No/Did not receive Vaccination #2; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation

Page 14 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		sis Set for Neutra rom All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason			
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2011020	Yes	Yes	Yes	Yes	Yes	Yes	
US2011029	Yes	Yes	Yes	Yes	Yes	Yes	
US2011048	Yes	Yes	Yes	Yes	Yes	Yes	
US2011051	Yes	Yes	Yes	Yes	Yes	Yes	
US2011055	Yes	Yes	Yes	Yes	Yes	No/Non study COVID-19 vaccine prior to the visit	
US2011061	Yes	Yes	Yes	Yes	Yes	Yes	
US2011084	Yes	Yes	Yes	Yes	Yes	Yes	
US2011087	Yes	Yes	Yes	Yes	Yes	Yes	
US2011090	Yes	Yes	Yes	Yes	Yes	Yes	
US2011091	Yes	Yes	Yes	Yes	Yes	Yes	
US2011092	Yes	Yes	Yes	Yes	Yes	Yes	
US2011093	Yes	Yes	Yes	Yes	Yes	Yes	

Page 15 of 66 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		et for Neutralizi		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2011095	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes
US2011102	Yes	Yes	Yes	Yes	Yes	Yes
US2021058	Yes	Yes	Yes	Yes	Yes	Yes
US2021064	Yes	Yes	Yes	Yes	Yes	Yes
US2021084	Yes	Yes	Yes	Yes	Yes	Yes
US2021090	Yes	Yes	Yes	Yes	Yes	Yes
US2021147	Yes	Yes	Yes	Yes	Yes	Yes
US2021166	Yes	Yes	Yes	Yes	Yes	Yes
US2021167	Yes	Yes	Yes	Yes	Yes	Yes
US2021179	Yes	Yes	Yes	Yes	Yes	Yes
US2031002	Yes	Yes	Yes	Yes	Yes	Yes
US2031004	Yes	Yes	Yes	Yes	Yes	Yes

Page 16 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		sis Set for Neutra rom All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2031011	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2031016	Yes	Yes	Yes	Yes	Yes	Yes
US2031030	Yes	Yes	Yes	Yes	Yes	Yes
US2031042	Yes	Yes	Yes	Yes	Yes	Yes
US2031051	Yes	Yes	Yes	Yes	Yes	Yes
US2031056	Yes	Yes	Yes	Yes	Yes	Yes
US2031057	Yes	Yes	Yes	Yes	Yes	Yes
US2031063	Yes	Yes	Yes	Yes	Yes	Yes
US2031066	Yes	Yes	Yes	Yes	Yes	Yes
US2031072	Yes	Yes	Yes	Yes	Yes	Yes
US2031080	Yes	Yes	Yes	Yes	Yes	Yes

Page 17 of 66 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		sis Set for Neutra rom All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2041002	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2041003	Yes	Yes	Yes	Yes	Yes	Yes
US2041006	Yes	Yes	Yes	Yes	Yes	Yes
US2041007	Yes	Yes	Yes	Yes	Yes	Yes
US2041012	Yes	Yes	Yes	Yes	Yes	Yes
US2041013	Yes	Yes	Yes	Yes	Yes	Yes
US2041016	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	·	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation; Post-baseline COVID-19 infection prior to the visit
US2041023	Yes	Yes	Yes	Yes	Yes	Yes

Page 18 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

	<u> </u>	sis Set for Neutra rom All Lots/Exclu	2	Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2041027	Yes	Yes	Yes	Yes	Yes	Yes
US2041030	Yes	Yes	Yes	Yes	Yes	Yes
US2041036	Yes	Yes	Yes	Yes	Yes	Yes
US2041047	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/Post-baselin e COVID-19 infection prior to the visit	No/There was no immunogenicity result at corresponding visit; Post-baseline COVID-19 infection prior to the visit
US2041049	Yes	Yes	No/There was no immunogenicity result at corresponding visit	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; There was no immunogenicity result at corresponding visit; Other study deviation
US2041051	Yes	Yes	Yes	Yes	Yes	Yes
US2041053	Yes	Yes	Yes	Yes	Yes	Yes

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

	-	et for Neutralizi: ll Lots/Exclusion	-	Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2041055	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation
US2041058	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation

Page 20 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

		sis Set for Neutralizi		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2041064	Yes	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; There was no immunogenicity result at corresponding visit; Other study deviation	No/Vaccination #2 out of window; There was no immunogenicity result at corresponding visit; Other study deviation
US2041071	Yes	Yes	Yes	Yes	Yes	Yes
US2041075	Yes	Yes	Yes	Yes	Yes	Yes
US2041076	Yes	Yes	Yes	Yes	Yes	Yes
US2041077	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2041088	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2041091	Yes	Yes	Yes	Yes	Yes	Yes

Page 21 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		sis Set for Neutra rom All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2041092	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2051008	Yes	Yes	Yes	Yes	Yes	Yes
US2051009	Yes	Yes	Yes	Yes	Yes	Yes
US2051010	Yes	Yes	Yes	Yes	Yes	Yes
US2051011	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	No/Serum collection out of window
US2051018	Yes	Yes	Yes	Yes	Yes	Yes
US2051027	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes
US2051031	Yes	Yes	Yes	Yes	Yes	Yes

Page 22 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

	_	sis Set for Neutralizi	-	Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2051032	Yes	Yes	Yes	Yes	Yes	Yes
US2051033	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes
US2051034	Yes	Yes	Yes	Yes	Yes	Yes
US2051038	Yes	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit
US2051040	Yes	Yes	Yes	Yes	Yes	Yes
US2051042	Yes	Yes	Yes	Yes	Yes	Yes
US2051043	Yes	Yes	Yes	Yes	Yes	Yes
US2051048	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window

Page 23 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		sis Set for Neutra rom All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason			
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2051050	Yes	Yes	Yes	Yes	Yes	Yes	
US2061001	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	
US2061006	Yes	Yes	Yes	Yes	Yes	Yes	
US2061009	Yes	Yes	Yes	Yes	Yes	Yes	
US2061011	Yes	Yes	Yes	Yes	Yes	Yes	
US2061013	Yes	Yes	Yes	Yes	Yes	Yes	
US2061019	Yes	Yes	Yes	Yes	Yes	Yes	
US2061026	Yes	Yes	Yes	Yes	Yes	Yes	
US2071001	Yes	Yes	Yes	Yes	Yes	Yes	
US2071003	Yes	Yes	Yes	Yes	Yes	Yes	
US2071004	Yes	Yes	Yes	Yes	Yes	Yes	

Page 24 of 66 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age  $\geq$  18 and age < 55); Vaccination Group: mRNA-1273 50 µg

	_	s Set for Neutralizi om All Lots/Exclusion	2	Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2071029	Yes	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation
US2071030	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes
US2071032	Yes	Yes	Yes	Yes	Yes	Yes
US2071033	Yes	Yes	Yes	No/Other study deviation	No/Other study deviation	No/Other study deviation
US2071063	Yes	Yes	Yes	Yes	Yes	Yes
US2071067	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes
US2071074	Yes	Yes	Yes	Yes	Yes	Yes
US2071081	Yes	Yes	Yes	Yes	Yes	Yes

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50  $\mu g$ 

	-	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2081036	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit	
US2081039	Yes	Yes	Yes	Yes	Yes	Yes	
US2081041	Yes	Yes	Yes	Yes	Yes	Yes	
US2081052	Yes	Yes	Yes	Yes	Yes	Yes	
US2081054	Yes	Yes	Yes	Yes	Yes	Yes	
US2081059	Yes	Yes	Yes	Yes	Yes	Yes	

Page 26 of 66 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		sis Set for Neutra rom All Lots/Excl		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2011018	Yes	Yes	Yes	Yes	Yes	Yes
US2011019	Yes	Yes	Yes	Yes	Yes	Yes
US2011039	Yes	Yes	Yes	Yes	Yes	Yes
US2011041	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit; Other study deviation
US2011046	Yes	Yes	Yes	Yes	Yes	Yes
US2011050	Yes	Yes	Yes	Yes	Yes	Yes
US2011059	Yes	Yes	Yes	Yes	Yes	Yes
US2011065	Yes	Yes	Yes	Yes	Yes	Yes
US2011080	Yes	Yes	Yes	Yes	Yes	Yes
US2011085	Yes	Yes	Yes	Yes	Yes	Yes
US2011089	Yes	Yes	Yes	Yes	Yes	Yes
US2011103	Yes	Yes	Yes	Yes	Yes	Yes

Page 27 of 66 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2021059	Yes	Yes	Yes	Yes	Yes	Yes	
US2021063	Yes	Yes	Yes	Yes	Yes	Yes	
US2021067	Yes	Yes	Yes	Yes	Yes	Yes	
US2021068	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window	
US2021074	Yes	Yes	Yes	Yes	Yes	Yes	
US2021080	Yes	Yes	Yes	Yes	Yes	Yes	
US2021093	Yes	Yes	Yes	Yes	Yes	Yes	
US2021099	Yes	Yes	Yes	Yes	Yes	Yes	
US2021101	Yes	Yes	Yes	Yes	Yes	Yes	
US2021121	Yes	Yes	Yes	Yes	Yes	Yes	
US2021145	Yes	Yes	Yes	Yes	Yes	Yes	
US2021151	Yes	Yes	Yes	Yes	Yes	Yes	
US2021154	Yes	Yes	Yes	Yes	Yes	Yes	
US2021164	Yes	Yes	Yes	Yes	Yes	Yes	

Page 28 of 66 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		sis Set for Neutra rom All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2021180	Yes	Yes	Yes	Yes	Yes	Yes
US2021182	Yes	Yes	Yes	Yes	No/Serum collection out of window	Yes
US2031012	Yes	Yes	Yes	Yes	Yes	Yes
US2031013	Yes	Yes	Yes	Yes	Yes	Yes
US2031019	Yes	Yes	Yes	Yes	Yes	Yes
US2031020	Yes	Yes	Yes	Yes	Yes	Yes
US2031021	Yes	Yes	Yes	Yes	Yes	Yes
US2031026	Yes	Yes	Yes	Yes	Yes	Yes
US2031027	Yes	Yes	Yes	Yes	Yes	Yes
US2031033	Yes	Yes	Yes	Yes	Yes	Yes
US2031035	Yes	Yes	Yes	Yes	Yes	Yes
US2031037	Yes	Yes	Yes	Yes	Yes	Yes
US2031047	Yes	Yes	Yes	Yes	Yes	Yes
US2031050	Yes	Yes	Yes	Yes	Yes	Yes

Page 29 of 66 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

		sis Set for Neutra rom All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2031060	Yes	Yes	Yes	Yes	Yes	Yes
US2031062	Yes	Yes	Yes	Yes	Yes	Yes
US2031073	Yes	Yes	Yes	Yes	Yes	Yes
US2031079	Yes	Yes	Yes	Yes	Yes	Yes
US2031084	Yes	Yes	Yes	Yes	Yes	Yes
US2041008	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes
US2041010	Yes	Yes	Yes	Yes	Yes	Yes
US2041024	Yes	Yes	Yes	Yes	Yes	Yes
US2041026	Yes	Yes	Yes	Yes	Yes	Yes
US2041041	Yes	Yes	Yes	Yes	Yes	Yes
US2041046	Yes	Yes	Yes	Yes	Yes	Yes
US2041048	Yes	Yes	Yes	Yes	Yes	Yes

Page 30 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason				Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2041060	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	
US2041061	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	
US2041073	Yes	Yes	Yes	Yes	Yes	Yes	
US2041079	Yes	Yes	Yes	Yes	Yes	Yes	
US2041080	Yes	Yes	Yes	Yes	Yes	Yes	
US2041084	Yes	Yes	Yes	Yes	Yes	Yes	
US2051001	Yes	Yes	Yes	Yes	Yes	Yes	
US2051002	Yes	Yes	Yes	Yes	Yes	Yes	
US2051003	Yes	Yes	No/There was rimmunogenicity result at corresponding visit		Yes	No/There was no immunogenicity result at corresponding visit	

Page 31 of 66 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

	Full Analysis S Antibody from A			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2051012	Yes	Yes	Yes	Yes	Yes	Yes
US2051013	Yes	Yes	Yes	Yes	Yes	Yes
US2051017	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes
US2051019	Yes	Yes	Yes	Yes	Yes	Yes
US2051020	Yes	Yes	Yes	Yes	Yes	Yes
US2051024	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit	-,	Yes
US2051025	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes
US2051026	Yes	Yes	Yes	Yes	Yes	Yes

Page 32 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

_	-	sis Set for Neutra rom All Lots/Exclu	2	Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2051028	Yes	Yes	Yes	No/Did not receive Vaccination #2; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation
US2051029	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes
US2051030	Yes	Yes	Yes	Yes	Yes	Yes
US2051045	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2061008	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window
US2061010	Yes	Yes	Yes	Yes	Yes	Yes

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

	_	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2061020	Yes	Yes	Yes	Yes	Yes	Yes	
US2061023	Yes	Yes	Yes	Yes	Yes	Yes	
US2061024	Yes	Yes	Yes	No/Dosing error	No/Dosing error	No/Dosing error	
US2061027	Yes	Yes	Yes	Yes	Yes	Yes	
US2071002	Yes	Yes	Yes	Yes	Yes	Yes	
US2071016	Yes	Yes	Yes	Yes	Yes	Yes	
US2071026	Yes	Yes	Yes	No/Other study deviation	No/Other study deviation	No/Other study deviation	
US2071036	Yes	Yes	Yes	Yes	Yes	Yes	
US2071038	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	

Page 34 of 66 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2071039	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/Vaccination #2 out of window; There was no immunogenicity result at corresponding visit; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2071040	Yes	Yes	Yes	Yes	Yes	Yes
US2071051	Yes	Yes	Yes	Yes	Yes	Yes
US2071068	Yes	Yes	Yes	Yes	Yes	Yes
US2071069	Yes	Yes	Yes	Yes	Yes	Yes
US2071071	Yes	Yes	Yes	Yes	Yes	Yes
US2071073	Yes	Yes	Yes	Yes	Yes	Yes
US2071077	Yes	Yes	Yes	Yes	Yes	Yes
US2081023	Yes	Yes	Yes	Yes	Yes	Yes
US2081025	Yes	Yes	Yes	Yes	Yes	Yes
US2081028	Yes	Yes	Yes	Yes	Yes	Yes

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100  $\mu g$ 

	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2081045	Yes	Yes	Yes	Yes	Yes	Yes
US2081051	Yes	Yes	Yes	Yes	Yes	Yes
US2081062	Yes	Yes	Yes	Yes	Yes	Yes
US2081063	Yes	Yes	Yes	Yes	Yes	Yes
US2081064	Yes	Yes	Yes	Yes	Yes	Yes

Cohort 2 (Age >= 55); Vaccination Group: Placebo

	_	is Set for Neutra om All Lots/Excl	_	Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason			
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	_
US2011007	Yes	Yes	Yes	Yes	Yes	Yes	
US2011011	Yes	Yes	Yes	Yes	Yes	Yes	
US2011023	Yes	Yes	Yes	Yes	Yes	Yes	
US2011109	Yes	Yes	Yes	Yes	Yes	Yes	
US2011114	Yes	Yes	Yes	Yes	Yes	Yes	
US2011116	Yes	Yes	Yes	Yes	Yes	Yes	
US2011120	Yes	Yes	Yes	Yes	Yes	Yes	
US2011124	Yes	Yes	Yes	Yes	Yes	Yes	
US2011126	Yes	Yes	Yes	Yes	Yes	Yes	
US2011130	Yes	Yes	Yes	Yes	Yes	Yes	
US2011131	Yes	Yes	Yes	Yes	Yes	Yes	
US2011142	Yes	Yes	Yes	Yes	Yes	Yes	
US2011145	Yes	Yes	Yes	Yes	Yes	Yes	
US2011152	Yes	Yes	Yes	Yes	Yes	Yes	
US2011155	Yes	Yes	Yes	Yes	Yes	Yes	

Cohort 2 (Age >= 55); Vaccination Group: Placebo

	-	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2011156	Yes	Yes	Yes	Yes	Yes	Yes	
US2011157	Yes	Yes	Yes	Yes	Yes	Yes	
US2021015	Yes	Yes	Yes	Yes	Yes	Yes	
US2021021	Yes	Yes	Yes	Yes	Yes	Yes	
US2021022	Yes	Yes	Yes	Yes	Yes	Yes	
US2021043	Yes	Yes	Yes	Yes	Yes	Yes	
US2021130	Yes	Yes	Yes	Yes	Yes	Yes	
US2021185	Yes	Yes	Yes	Yes	Yes	Yes	
US2021189	Yes	Yes	Yes	Yes	Yes	Yes	
US2021196	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit	

Page 38 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		s Set for Neutra om All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2021198	Yes	Yes	No/There was no immunogenicity result at corresponding visit	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; There was no immunogenicity result at corresponding visit; Other study deviation
US2021206	Yes	Yes	Yes	Yes	Yes	Yes
US2021207	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2021219	Yes	Yes	Yes	Yes	Yes	Yes
US2021222	Yes	Yes	Yes	Yes	Yes	Yes
US2031085	Yes	Yes	Yes	Yes	Yes	Yes
US2031089	Yes	Yes	Yes	Yes	Yes	Yes
US2031092	Yes	Yes	Yes	Yes	Yes	Yes

Cohort 2 (Age >= 55); Vaccination Group: Placebo

	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2031095	Yes	Yes	Yes	Yes	Yes	Yes
US2031098	Yes	Yes	Yes	Yes	Yes	Yes
US2031100	Yes	Yes	Yes	Yes	Yes	Yes
US2031102	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit	No/Post-baselin e COVID-19 infection prior to the visit
US2031103	Yes	Yes	Yes	Yes	Yes	Yes
US2031110	Yes	Yes	Yes	Yes	Yes	Yes
US2031116	Yes	Yes	Yes	Yes	Yes	Yes
US2031124	Yes	Yes	Yes	Yes	Yes	Yes
US2031125	Yes	Yes	Yes	Yes	Yes	Yes
US2031129	Yes	Yes	Yes	Yes	Yes	Yes
US2031131	Yes	Yes	Yes	Yes	Yes	Yes
US2041102	Yes	Yes	Yes	Yes	Yes	Yes

Page 40 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		sis Set for Neutra rom All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2041114	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2041115	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2041121	Yes	Yes	Yes	Yes	Yes	Yes
US2041132	Yes	Yes	Yes	Yes	Yes	Yes
US2041142	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2041146	Yes	Yes	Yes	Yes	Yes	Yes
US2041151	Yes	Yes	Yes	Yes	Yes	Yes
US2041152	Yes	Yes	Yes	Yes	Yes	Yes

Cohort 2 (Age >= 55); Vaccination Group: Placebo

	_	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2041166	Yes	Yes	Yes	Yes	Yes	Yes	
US2051055	Yes	Yes	Yes	Yes	Yes	Yes	
US2051063	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit	
US2051072	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation; Post-baseline COVID-19 infection prior to the visit	No/Post-baselin e COVID-19 infection prior to the visit	
US2051073	Yes	Yes	Yes	Yes	Yes	Yes	
US2051086	Yes	Yes	Yes	Yes	Yes	Yes	
US2051087	Yes	Yes	Yes	Yes	Yes	Yes	
US2051089	Yes	Yes	Yes	Yes	Yes	Yes	

Page 42 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2051098	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2051112	Yes	Yes	Yes	Yes	Yes	Yes
US2061035	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation; Post-baseline COVID-19 infection prior to the visit
US2061043	Yes	Yes	Yes	Yes	Yes	Yes
US2061046	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit
US2061051	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window

Cohort 2 (Age >= 55); Vaccination Group: Placebo

	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2061055	Yes	Yes	Yes	Yes	Yes	Yes
US2071005	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit
US2071041	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit
US2071084	Yes	Yes	Yes	Yes	Yes	Yes
US2071085	Yes	Yes	Yes	Yes	Yes	Yes
US2071086	Yes	Yes	Yes	Yes	Yes	Yes
US2071088	Yes	Yes	Yes	Yes	Yes	Yes
US2071092	Yes	Yes	Yes	Yes	Yes	No/Post-baselin e COVID-19 infection prior to the visit
US2071094	Yes	Yes	Yes	Yes	Yes	Yes
US2071098	Yes	Yes	Yes	No/Other study deviation	No/Other study deviation	No/Other study deviation

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		sis Set for Neutra rom All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2071100	Yes	Yes	Yes	Yes	Yes	Yes
US2071102	Yes	Yes	Yes	Yes	Yes	Yes
US2071103	Yes	Yes	Yes	Yes	No/Serum collection out of window	Yes
US2071105	Yes	Yes	Yes	Yes	Yes	Yes
US2081004	Yes	Yes	Yes	Yes	Yes	Yes
US2081005	Yes	Yes	Yes	Yes	Yes	Yes
US2081007	Yes	Yes	Yes	Yes	Yes	Yes
US2081015	Yes	Yes	Yes	Yes	Yes	Yes
US2081017	Yes	Yes	Yes	Yes	Yes	Yes
US2081029	Yes	Yes	Yes	Yes	Yes	Yes
US2081030	Yes	Yes	Yes	Yes	Yes	Yes
US2081065	Yes	Yes	Yes	Yes	Yes	Yes
US2081066	Yes	Yes	Yes	Yes	Yes	Yes

Cohort 2 (Age >= 55); Vaccination Group: Placebo

	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2081073	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2081077	Yes	Yes	Yes	Yes	Yes	Yes
US2081080	Yes	Yes	Yes	Yes	Yes	Yes
US2081087	Yes	Yes	Yes	Yes	Yes	Yes
US2081097	Yes	Yes	Yes	Yes	Yes	Yes
US2081103	Yes	Yes	Yes	Yes	Yes	Yes
US2081104	Yes	Yes	Yes	Yes	Yes	Yes
US2081113	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window

Cohort 2 (Age >= 55); Vaccination Group: Placebo

	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2081119	Yes	Yes	No/There was no immunogenicity result at corresponding visit	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; There was no immunogenicity result at corresponding visit; Other study deviation
US2081125	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

	_	sis Set for Neutra rom All Lots/Excl	_	Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2011012	Yes	Yes	Yes	Yes	Yes	Yes
US2011014	Yes	Yes	Yes	Yes	Yes	Yes
US2011032	Yes	Yes	Yes	Yes	Yes	Yes
US2011040	Yes	Yes	Yes	Yes	Yes	Yes
US2011117	Yes	Yes	Yes	Yes	Yes	Yes
US2011123	Yes	Yes	Yes	Yes	Yes	Yes
US2011125	Yes	Yes	Yes	Yes	Yes	Yes
US2011127	Yes	Yes	Yes	Yes	Yes	Yes
US2011137	Yes	Yes	Yes	Yes	Yes	Yes
US2011138	Yes	Yes	Yes	Yes	Yes	Yes
US2011153	Yes	Yes	Yes	Yes	Yes	Yes
US2021004	Yes	Yes	Yes	Yes	Yes	Yes
US2021012	Yes	Yes	Yes	Yes	Yes	Yes
US2021018	Yes	Yes	Yes	Yes	Yes	Yes
US2021019	Yes	Yes	Yes	Yes	Yes	Yes

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		sis Set for Neutra rom All Lots/Exclu			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2021020	Yes	Yes	Yes	Yes	Yes	Yes	
US2021045	Yes	Yes	Yes	Yes	Yes	Yes	
US2021047	Yes	Yes	Yes	Yes	Yes	Yes	
US2021133	Yes	Yes	Yes	Yes	Yes	Yes	
US2021190	Yes	Yes	Yes	Yes	Yes	Yes	
US2021192	Yes	Yes	Yes	Yes	Yes	Yes	
US2021205	Yes	Yes	Yes	Yes	Yes	Yes	
US2021216	Yes	Yes	Yes	Yes	Yes	Yes	
US2021217	Yes	Yes	Yes	Yes	Yes	Yes	
US2021220	Yes	Yes	Yes	Yes	Yes	Yes	
US2021226	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window	
US2031086	Yes	Yes	Yes	Yes	Yes	Yes	
US2031096	Yes	Yes	Yes	Yes	Yes	Yes	
US2031097	Yes	Yes	Yes	Yes	Yes	Yes	

Page 49 of 66 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

			et for Neutralizing ll Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2031104	Yes	Yes	Yes	Yes	Yes	Yes	
US2031105	Yes	Yes	Yes	Yes	Yes	Yes	
US2031106	Yes	Yes	Yes	Yes	Yes	Yes	
US2031107	Yes	Yes	Yes	Yes	No/Serum collection out of window	Yes	
US2031108	Yes	Yes	Yes	Yes	Yes	Yes	
US2031109	Yes	Yes	Yes	Yes	Yes	Yes	
US2031114	Yes	Yes	Yes	Yes	Yes	Yes	
US2031121	Yes	Yes	Yes	Yes	Yes	Yes	
US2031128	Yes	Yes	Yes	Yes	Yes	Yes	
US2041094	Yes	Yes	Yes	Yes	Yes	Yes	
US2041100	Yes	Yes	Yes	Yes	Yes	Yes	
US2041103	Yes	Yes	Yes	Yes	Yes	Yes	
US2041104	Yes	Yes	Yes	Yes	Yes	Yes	

Page 50 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		sis Set for Neutra rom All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2041106	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2041109	Yes	Yes	Yes	Yes	Yes	Yes
US2041111	Yes	Yes	Yes	Yes	Yes	Yes
US2041113	Yes	Yes	Yes	Yes	Yes	Yes
US2041118	Yes	Yes	Yes	Yes	Yes	Yes
US2041119	Yes	Yes	Yes	Yes	Yes	Yes
US2041127	Yes	Yes	Yes	Yes	Yes	Yes
US2041130	Yes	Yes	Yes	Yes	Yes	Yes
US2041139	Yes	Yes	Yes	Yes	Yes	Yes
US2041145	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2041150	Yes	Yes	Yes	Yes	Yes	Yes

Page 51 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		sis Set for Neutra rom All Lots/Excl		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2041155	Yes	Yes	Yes	Yes	Yes	Yes
US2051057	Yes	Yes	Yes	Yes	Yes	Yes
US2051059	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes
US2051060	Yes	Yes	Yes	Yes	Yes	Yes
US2051066	Yes	Yes	Yes	Yes	Yes	Yes
US2051068	Yes	Yes	Yes	Yes	Yes	Yes
US2051071	Yes	Yes	Yes	Yes	Yes	Yes
US2051078	Yes	Yes	Yes	Yes	Yes	Yes
US2051081	Yes	Yes	Yes	Yes	Yes	Yes
US2051092	Yes	Yes	Yes	Yes	Yes	Yes
US2051093	Yes	Yes	Yes	Yes	Yes	Yes
US2051094	Yes	Yes	Yes	Yes	Yes	Yes
US2051095	Yes	Yes	Yes	Yes	Yes	Yes

Page 52 of 66 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		sis Set for Neutra rom All Lots/Exclu			ol Set for Neutral rom All Lots/Excl	
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2051096	Yes	Yes	Yes	Yes	Yes	Yes
US2051099	Yes	Yes	Yes	Yes	Yes	Yes
US2051100	Yes	Yes	Yes	Yes	Yes	Yes
US2051103	Yes	Yes	Yes	Yes	Yes	Yes
US2051105	Yes	Yes	Yes	Yes	Yes	Yes
US2051107	Yes	Yes	Yes	Yes	Yes	Yes
US2051109	Yes	Yes	Yes	Yes	Yes	Yes
US2061037	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window
US2061053	Yes	Yes	Yes	Yes	Yes	Yes
US2061057	Yes	Yes	Yes	Yes	Yes	Yes
US2061064	Yes	Yes	Yes	Yes	Yes	Yes
US2061068	Yes	Yes	Yes	Yes	Yes	Yes
US2071007	Yes	Yes	Yes	Yes	Yes	Yes
US2071024	Yes	Yes	Yes	Yes	Yes	Yes

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

	_	et for Neutralizi	-	Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2071025	Yes	Yes	Yes	Yes	Yes	Yes
US2071083	Yes	Yes	Yes	Yes	Yes	Yes
US2071090	Yes	Yes	Yes	Yes	Yes	Yes
US2071099	Yes	Yes	Yes	Yes	Yes	Yes
US2071101	Yes	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation
US2071104	Yes	Yes	Yes	Yes	Yes	Yes
US2071106	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation; Post-baseline COVID-19 infection prior to the visit	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation; Post-baseline COVID-19 infection prior to the visit

Page 54 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		sis Set for Neutra rom All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2081003	Yes	Yes	Yes	Yes	Yes	Yes
US2081009	Yes	Yes	Yes	Yes	Yes	Yes
US2081020	Yes	Yes	Yes	Yes	Yes	Yes
US2081070	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2081071	Yes	Yes	Yes	Yes	Yes	Yes
US2081085	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation
US2081090	Yes	Yes	Yes	Yes	Yes	Yes
US2081092	Yes	Yes	Yes	Yes	Yes	Yes

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2081100	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes
US2081110	Yes	Yes	Yes	Yes	Yes	Yes
US2081112	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2081118	Yes	Yes	Yes	Yes	Yes	Yes
US2081123	Yes	Yes	Yes	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation

Page 56 of 66 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		sis Set for Neutra rom All Lots/Excl		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2011004	Yes	Yes	Yes	Yes	Yes	Yes
US2011009	Yes	Yes	Yes	Yes	Yes	Yes
US2011028	Yes	Yes	Yes	Yes	Yes	Yes
US2011113	Yes	Yes	Yes	Yes	Yes	Yes
US2011118	Yes	Yes	Yes	Yes	Yes	Yes
US2011121	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2011122	Yes	Yes	Yes	Yes	Yes	Yes
US2011128	Yes	Yes	Yes	Yes	Yes	Yes
US2011139	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2011149	Yes	Yes	Yes	Yes	Yes	Yes
US2011159	Yes	Yes	Yes	Yes	Yes	Yes

Page 57 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

	_	et for Neutralizi	-	Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2011162	No/There was no immunogenicity result at baseline	No/There was no immunogenicity result at baseline	No/There was no immunogenicity result at baseline	No/Not in Full Analysis Set	No/Not in Full Analysis Set	No/Not in Full Analysis Set
US2021003	Yes	Yes	Yes	Yes	Yes	Yes
US2021007	Yes	Yes	Yes	Yes	Yes	Yes
US2021011	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window
US2021031	Yes	Yes	Yes	Yes	Yes	Yes
US2021114	Yes	Yes	Yes	Yes	Yes	Yes
US2021115	Yes	Yes	Yes	Yes	Yes	Yes
US2021186	Yes	Yes	Yes	Yes	Yes	Yes
US2021208	Yes	Yes	Yes	Yes	No/Serum collection out of window	Yes
US2021211	Yes	Yes	Yes	Yes	Yes	Yes
US2021214	Yes	Yes	Yes	Yes	Yes	Yes

Page 58 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		sis Set for Neutra rom All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2021215	Yes	Yes	Yes	Yes	No/Serum collection out of window	Yes
US2021218	Yes	Yes	Yes	Yes	Yes	Yes
US2021230	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Post-baseline COVID-19 infection prior to the visit
US2021232	Yes	Yes	Yes	Yes	Yes	Yes
US2021234	Yes	Yes	Yes	Yes	Yes	Yes
US2031091	Yes	Yes	Yes	Yes	Yes	Yes
US2031093	Yes	Yes	Yes	Yes	Yes	Yes
US2031101	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2031111	Yes	Yes	Yes	Yes	Yes	Yes

Page 59 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

		Set for Neutraliza		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2031112	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes
US2031122	Yes	Yes	Yes	Yes	Yes	Yes
US2041096	Yes	Yes	Yes	Yes	Yes	Yes
US2041107	Yes	Yes	Yes	Yes	Yes	Yes
US2041108	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes
US2041112	Yes	Yes	Yes	Yes	Yes	Yes
US2041117	Yes	Yes	Yes	Yes	Yes	Yes
US2041120	Yes	Yes	Yes	Yes	Yes	Yes
US2041122	Yes	Yes	Yes	Yes	Yes	Yes
US2041123	Yes	Yes	Yes	Yes	Yes	Yes
US2041125	Yes	Yes	Yes	Yes	Yes	Yes

Page 60 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		sis Set for Neutra rom All Lots/Exclu		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2041126	Yes	Yes	Yes	Yes	Yes	Yes
US2041131	Yes	Yes	No/There was no immunogenicity result at corresponding visit	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; There was no immunogenicity result at corresponding visit; Other study deviation
US2041136	Yes	Yes	Yes	Yes	Yes	Yes
US2041138	Yes	Yes	Yes	Yes	Yes	Yes
US2041144	Yes	Yes	Yes	Yes	Yes	Yes
US2041149	Yes	Yes	Yes	Yes	Yes	Yes
US2051054	Yes	Yes	Yes	Yes	Yes	Yes
US2051064	Yes	Yes	Yes	Yes	Yes	Yes
US2051069	Yes	Yes	Yes	Yes	Yes	Yes
US2051070	Yes	Yes	Yes	Yes	Yes	Yes
US2051074	Yes	Yes	Yes	Yes	Yes	Yes

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason				Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2051075	Yes	Yes	Yes	Yes	Yes	Yes	
US2051077	Yes	Yes	Yes	Yes	Yes	Yes	
US2051084	Yes	Yes	Yes	Yes	Yes	Yes	
US2051085	Yes	Yes	Yes	Yes	Yes	Yes	
US2051088	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit	
US2051097	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit	
US2051101	Yes	Yes	Yes	Yes	Yes	Yes	
US2051102	Yes	Yes	Yes	Yes	Yes	Yes	

Page 62 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 μg

	-	et for Neutralizi	-	Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2051104	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2051106	Yes	Yes	Yes	Yes	Yes	Yes
US2051108	Yes	Yes	Yes	Yes	Yes	Yes
US2051111	Yes	Yes	Yes	Yes	Yes	Yes
US2061036	Yes	Yes	Yes	Yes	Yes	Yes
US2061045	Yes	Yes	Yes	Yes	No/Serum collection out of window	Yes
US2061063	Yes	Yes	Yes	Yes	Yes	Yes
US2071006	Yes	Yes	Yes	Yes	Yes	Yes

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 μg

	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason			
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2071013	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	
US2071037	Yes	Yes	Yes	Yes	Yes	Yes	
US2071043	Yes	Yes	Yes	Yes	Yes	Yes	
US2071082	Yes	Yes	Yes	Yes	Yes	Yes	
US2071087	Yes	Yes	Yes	Yes	Yes	Yes	
US2071089	Yes	Yes	Yes	Yes	Yes	Yes	
US2071091	Yes	Yes	Yes	Yes	Yes	Yes	
US2071093	Yes	Yes	Yes	Yes	Yes	Yes	
US2071095	Yes	Yes	Yes	Yes	Yes	Yes	

Page 64 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason			
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2071096	No/There was no Yes immunogenicity result at corresponding visit		Yes	No/There was no immunogenicity result at corresponding visit; Other study deviation	No/Other study deviation	No/Other study deviation	
US2081001	Yes	Yes	Yes	Yes	Yes	Yes	
US2081002	Yes	Yes	Yes	Yes	Yes	Yes	
US2081014	Yes	Yes	Yes	Yes	Yes	Yes	
US2081016	Yes	Yes	Yes	Yes	Yes	Yes	
US2081019	Yes	Yes	Yes	Yes	Yes	Yes	
US2081035	Yes	Yes	Yes	Yes	Yes	Yes	
US2081069	Yes	Yes	Yes	Yes	Yes	Yes	
US2081072	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit	
US2081075	Yes	Yes	Yes	Yes	Yes	Yes	

Cohort 2 (Age  $\geq$  55); Vaccination Group: mRNA-1273 100 µg

	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason			
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209	
US2081076	Yes	Yes	Yes	Yes	Yes	Yes	
US2081081	Yes	Yes	Yes	Yes	Yes	Yes	
US2081088	Yes	Yes	Yes	Yes	Yes	Yes	
US2081091	Yes	Yes	Yes	Yes	Yes	Yes	
US2081093	Yes	Yes	Yes	Yes	Yes	Yes	
US2081099	Yes	Yes	Yes	Yes	Yes	Yes	
US2081108	Yes	Yes	Yes	Yes	Yes	Yes	
US2081116	Yes	Yes	Yes	Yes	Yes	Yes	
US2081117	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	
US2081120	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit	

Page 66 of 66
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.3.2 Analysis Sets 2 Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 μg

	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason			Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason		
Subject ID	Day 29	Day 57	Day 209	Day 29	Day 57	Day 209
US2081121	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2081129	Yes	Yes	Yes	Yes	Yes	Yes